Pre-made Imsidolimab benchmark antibody ( Whole mAb, anti-IL36R/IL1RL2 therapeutic antibody, Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Imsidolimab biosimilar, Whole mAb, Anti-IL36R/IL1RL2 Antibody: Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis (GPP), EGFRi-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-269-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Imsidolimab biosimilar, Whole mAb, Anti-IL36R/IL1RL2 Antibody: Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody
INN Name	Imsidolimab
Target	IL1RL2
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	AnaptysBio
Conditions Approved	na
Conditions Active	Generalised pustular psoriasis;Localised pustular psoriasis
Conditions Discontinued	na
Development Tech	na